PLX Stock Summary and Trading Ideas (Protalix Biotherapeutics (De) | AMEX:PLX)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.

As of May 1, 2026, PLX stock price declined to $2.12 with 364,177 million shares trading.

PLX has a beta of 1.92, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.10 to the broad based SPY ETF.

PLX has a market cap of $170.81 million. This is considered a Micro Cap stock.

Last quarter Protalix Biotherapeutics (De) reported $9 million in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.07.

In the last 3 years, PLX traded as high as $3.55 and as low as $.82.

The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, DFAS, IWC.

PLX has underperformed the market in the last year with a price return of -30.9% while the SPY ETF gained +31.5%. PLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.4% and -7.8%, respectively, while the SPY returned +4.6% and +2.9%, respectively.

PLX support price is $2.10 and resistance is $2.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.